YUNIK FARMASYUTIKAL LABORATORIZ, OOO

FDA Announces Nationwide Cetirizine Recall After Cross-Contamination with Ranitidine Discovered

- Unique Pharmaceutical Laboratories voluntarily recalled four lots of 5 mg cetirizine hydrochloride tablets after a pharmacy technician discovered red dots and discoloration on tablets, later identified as ranitidine contamination. - The affected lots (GY825029–GY825032) carry an October 2028 expiration date and were distributed nationwide through wholesalers and pharmacies via Rising Pharma Holdings. - For individuals with ranitidine sensitivity, accidental ingestion could trigger severe hypersensitivity reactions including anaphylaxis, though no adverse events have been reported to date. - Consumers are advised to check lot numbers and visually inspect tablets, discontinuing use if contamination is suspected, and may contact Rising Pharma at 1-844-874-7464 for return arrangements.